001367.SZ
海森药业
SZSE · C 制造业 · CN
CNY 20.44
−6.24%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 521.0M | 532.3M | 471.5M | 397.5M | 422.8M |
| Cost of Revenue | 279.0M | 289.5M | 276.0M | 234.2M | 264.8M |
| Gross Profit | 242.0M | 242.7M | 195.5M | 163.3M | 158.0M |
| Operating Expenses | |||||
| R&D Expense | 38.8M | 38.9M | 27.8M | 18.8M | 15.8M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 37.3M | 37.0M | 30.7M | 26.0M | 22.7M |
| Selling & Marketing Expense | 16.5M | 16.2M | 12.4M | 10.5M | 10.0M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 95.6M | 91.7M | 57.1M | 43.6M | 39.1M |
| Cost and Expenses | 374.6M | 381.2M | 333.0M | 277.7M | 303.9M |
| Operating Income (EBIT) | 154.2M | 156.8M | 142.0M | 122.0M | 121.6M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 153.7M | 156.8M | 141.8M | 120.7M | 123.8M |
| Income Tax Expense | 20.1M | 20.9M | 19.2M | 16.0M | 16.2M |
| Bottom Line | |||||
| Net Income | 133.6M | 135.9M | 122.6M | 104.7M | 107.6M |
| Earnings from Cont. Ops | 133.6M | 135.9M | 122.6M | 104.7M | 107.6M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 133.6M | 135.9M | 122.6M | 104.7M | 107.6M |
| Per Share | |||||
| Basic EPS | CN¥0.89 | CN¥0.91 | CN¥0.82 | CN¥1.13 | CN¥2.11 |
| Diluted EPS | CN¥0.89 | CN¥0.89 | CN¥0.82 | CN¥1.13 | CN¥2.11 |
| Revenue Per Share | CN¥3.42 | CN¥3.56 | CN¥3.15 | CN¥4.29 | CN¥8.29 |
| Shares | |||||
| Basic Shares Outstanding | 152.1M | 149.3M | 149.5M | 92.6M | 51.0M |
| Diluted Shares Outstanding | 152.1M | 149.3M | 149.5M | 92.6M | 51.0M |
| Profitability Metrics | |||||
| EBITDA | — | 179.4M | 157.9M | 136.6M | 136.9M |
| D&A | — | 22.5M | 15.8M | 14.6M | 15.2M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026